Anti-PD-L1 inhibitors atezolizumab and durvalumab both improved the survival benefits of chemotherapy for SCLC patients, but atezolizumab monotherapy or durvalumab monotherapy failed in second-line therapy for refractory SCLC patients. Here, CD274 is linked to small cell lung carcinoma.